Gilead Sciences, Inc. GILD

$GILD Undervalued big time!

$GILD Tremendously Good numbers!!!!

$GILD BLOW OUT EARNINGS!!! ??????????
?????????

$GILD Big Beat!! ??????

$GILD Solid move up. More to come ??

$CRBU
Take a look at Caribou Biosciences. $CRBU

Leader in CRISPR Gene editing. Cure to all diseases.

Founded by Nobel winner Jennifer Doudna and CEO Rachel Haurwitz.

Market cap 1.5 Billion.

They have 14,453,932 shares of Intellia (NTLA). Worth $2.5 Billion alone. Check out filings:

https://www.sec.gov/edgar/browse/?CIK=1619856&owner=exclude

They have about $500 Million in cash from recent IPO.

Listen to The Code Breaker by Walter Isaacson on Audible. https://www.audible.com/pd?asin=179711705X&source_code=ASSORAP0511160006

Check out patents:

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=AN%2FCaribou&Refine=Refine+Search&Query=AN%2FCaribou+AND+Biosciences

Working on cure for cancer.

https://www.cariboubio.com

This has potential for x 1000

New CRISPR/Cas9 patent issued to Carribou Bio recently

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11,111,506&OS=11,111,506&RS=11,111,506

Do your own due diligence.

Good luck

$GILD Gilead Sciences (GILD) Remains Undervalued Despite Outperformance - Oppenheimer

Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $100.00 price target on Gilead Sciences (NASDAQ: GILD) noting that late 2020, the company has steadily been delivering positive pipeline updates (Yescarta in 2nd-line LBCL), while prepping investors for a raft of approaching clinical/regulatory catalysts. Despite this, the analyst detects 'categorical negative sentiment' often expressed by investors.

The analyst stated "We believe that starting with Yescarta's recent 2nd-line success (possibly adding margin ≥2022), the domino effect for GILD's oncology and virology pipeline could be in play. With remdesivir potentially having a long revenue tail against COVID-19 (also GILD developing orals) and fundamentals improving, we believe investors should pay heed."

$GILD Gilead Sciences wins reversal of $1.2 billion award in patent case with Bristol Myers ??????

$GILD Gilead Sciences (NASDAQ:GILD) Earns Buy Rating from Royal Bank of Canada

Gilead Sciences logoGilead Sciences (NASDAQ:GILD)'s stock had its "buy" rating restated by stock analysts at Royal Bank of Canada in a research report issued to clients and investors on Monday, TipRanks reports. They currently have a C$84.00 target price on the biopharmaceutical company's stock.

$GILD Finally getting its due!!! ????